Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610127 · ClinicalTrials.gov registry record
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 53
- Enrollment target
NCT02610127: Completed study, sponsored by Baxalta now part of Shire.
NCT02610127 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02610127 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
The overall objective is to enroll patients with acquired hemophilia A (AHA) who are prescribed and treated with Obizur, to assess safety, and to describe factors related to safety, utilization and effectiveness in a real-world setting.
Interventions
- BIOLOGICAL OBIZUR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2015-12-30 |
| Est. Completion | 2019-06-07 |
What the finished NCT02610127 record still lists
NCT02610127 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which OBIZUR is the first listed.
NCT02610127 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02610127 about?
NCT02610127 is a clinical study titled "Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A". The overall objective is to enroll patients with acquired hemophilia A (AHA) who are prescribed and treated with Obizur, to assess safety, and to describe factors related to safety, utilization and effectiveness in a real-world setting.
What is the current status of trial NCT02610127?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2015-12-30. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT02610127?
The interventions under investigation include: OBIZUR (BIOLOGICAL).
Who is sponsoring clinical trial NCT02610127?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI